A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluate the safety and tolerability of GW786034 in patients with relapsed or refractory multiple myeloma (MM).
GSK Clinical Trials
Study Director
GlaxoSmithKline
Australia: National Health and Medical Research Council
VEG20006
NCT00256880
January 2005
December 2005
Name | Location |
---|---|
GSK Investigational Site | Little Rock, Arkansas 72205 |
GSK Investigational Site | Springfield, Massachusetts 01107 |
GSK Investigational Site | Raleigh, North Carolina 27609 |
GSK Investigational Site | Pittsburgh, Pennsylvania 15213 |
GSK Investigational Site | Seattle, Washington 98133 |